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Abstract: The AKT (protein kinase B, PKB) family has been shown to participate in diverse cellular
processes, including apoptosis. Previous studies demonstrated that protein kinase B2 (AKT2−/−)
mice heart was sensitized to apoptosis in response to ischemic injury. However, little is known
about the mechanism and apoptotic signaling pathway. Here, we show that AKT2 inhibition
does not affect the development of cardiomyocytes but increases cell death during cardiomyocyte
ischemia. Caspase-dependent apoptosis of both the extrinsic and intrinsic pathway was inactivated
in cardiomyocytes with AKT2 inhibition during ischemia, while significant mitochondrial disruption
was observed as well as intracytosolic translocation of cytochrome C (Cyto C) together with
apoptosis-inducing factor (AIF) and endonuclease G (EndoG), both of which are proven to conduct
DNA degradation in a range of cell death stimuli. Therefore, mitochondria-dependent cell death
was investigated and the results suggested that AIF and EndoG nucleus translocation causes
cardiomyocyte DNA degradation during ischemia when AKT2 is blocked. These data are the
first to show a previous unrecognized function and mechanism of AKT2 in regulating cardiomyocyte
survival during ischemia by inducing a unique mitochondrial-dependent DNA degradation pathway
when it is inhibited.
Keywords: cardiomyocytes; apoptosis; protein kinase B2 (AKT2); ischemia; apoptosis-inducing
factor (AIF); endonuclease G (EndoG)
1. Introduction
Apoptosis is defined as programmed cell death (PCD), which is executed by a family of cysteinyl
aspartate proteinases known as caspases [1]. Caspases belong to a family of highly conserved
aspartate-specific cysteine proteases that are expressed as inactive zymogens in most animal cells
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and serve as the central executioners of apoptosis [2]. When activated, these enzymes cleave their
protein substrates on the carboxy-terminal side of an aspartate residue [3]. There are two signaling
pathways involved in PCD. The death receptor pathway (the extrinsic pathway), involved in the
activation of caspase-8 and -10, is initiated when death receptors are stimulated. An alternative
pathway (the intrinsic pathway) involves the activation of caspase-9, which relies on the release of
cytochrome c (Cyto C) and other mitochondrial proteins in the cytoplasm, and this process is controlled
by B-cell lymphoma-2 (Bcl-2) family proteins [4]. Once caspases-3, -6, and -7 are activated, they cleave
a variety of proteins or death substrates. During early apoptosis, caspase-3 cleaves poly (ADP-ribose)
polymerase (PARP), which decreases its DNA repair activity and leads to apoptotic cell death [5].
Mitochondria play a key part in the regulation of apoptosis [6]. Endonuclease G (EndoG),
a well-conserved nuclease, is a homodimer that is considered to be involved in mitochondrial DNA
replication with important roles in DNA recombination and repair. EndoG is localized in the mitochondria,
and then translocates to the nucleus during apoptosis with cell death stimuli such as truncated BH3
interacting-domain death agonist (tBid), tumor-necrosis factor-alpha (TNF-α) and ultraviolet (UV)
irradiation [7]. Biochemical and genetic studies have identified EndoG as one of the endonucleases
important for mammalian DNA fragmentation during apoptosis [7]. Apoptosis-inducing factor (AIF) is
normally confined to mitochondria but translocates to the nucleus in response to specific death signals [8,9].
It is reported that AIF causes high molecular weight DNA fragmentation and chromatin condensation
in cells and isolated nuclei in a caspase-independent manner [9,10]. Previous research by Bahi and
coworkers has demonstrated that the release of EndoG together with AIF from mitochondria to cytosol
in rat postnatal differentiated cardiomyocytes is induced by experimental ischemia and causes DNA
degradation in cardiomyocytes thereafter [11]. However, the involvement of EndoG and AIF in
cardiomyocytes with AKT2 inhibition during ischemia still remains unclear.
AKT is a serine/threonine protein kinase that is activated by a number of growth factors or
cytokines in a phosphatidylinositol-3 kinase (PI3K)-dependent manner [12]. The AKT family consists
of three isoforms—AKT1, AKT2 and AKT3, each of them encoded by distinct, highly conserved
genes [13]. All three isoforms are expressed in the myocardium with AKT1 and AKT2 comprising
the vast majority of total AKT protein in the heart [14]. Of the three isoforms of AKT, AKT2 is
reported to play a critical role in antagonizing cardiomyocyte apoptosis that occurs in response to a
variety of stimuli [15]. However, the function of AKT2 deficiency on cardiac ischemia/reperfusion
(I/R) injury is controversial, with most reports suggesting AKT2−/− cardiomyocytes were sensitized
to apoptosis [13,15,16], and one supporting a beneficial effect during cardiac I/R [17]. Despite the
controversy of AKT2 function on cardiac I/R injury, the molecular mechanisms regulating this cell
death remain poorly defined.
To gain a better understanding of the AKT2 isoform in the heart during ischemia, we used specific
AKT2 inhibitor to directly examine the role of AKT2 during ischemia-induced apoptosis and the
signaling pathway in neonatal rat cardiomyocytes (NRCMs) because of the low survival of primary
cardiomyocytes directly obtained from the heart of AKT2 knockout (KO) mice for in vitro study. In our
study, we demonstrate that ischemic stimuli induce the release of mitochondrial factors involved in
cell death induction in NRCMs with AKT2 inhibition. Indeed, we show that the mitochondrial outer
membrane permeabilization induced by bcl-2-like protein 4 (Bax) results in the release of apoptotic
factors including Cyto C, AIF and EndoG into the cytosol and causes cell death by inducing DNA
degradation without caspase activation when AKT2 is blocked. Our results provide the evidence that
AIF and EndoG are two important factors involved in the regulation of caspase-independent cell death
induced by ischemia-mediated cardiomyocte injury when AKT2 is inhibited.
Our study provides a novel view of AKT2 function on ischemic NRCMs that was not elucidated
previously and hence gains a better understanding of different cell death pathways that are provoked
in ischemic NRCMs with AKT2 inhibition.
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2. Results
2.1. AKT2 Inhibition Induces Elevation of Apoptotic Gene Expression in Myocardium without Affecting
Myocyte Development
In order to investigate the role of AKT2 in the myocyte during ischemia, we initially compared
apoptosis-related genes and observed slight increase of genes involved in mitochondrial-dependent
apoptosis in NRCMs treated with a specific AKT2 inhibitor (Figure 1A, left panel). The same result was
also observed in AKT2 knockout (AKT2 KO) mice hearts when compared with wild-type (WT) hearts
(Figure 1A, right panel). To ascertain if NRCM development is affected by the changes of apoptotic
gene expression, we compared hearts of AKT2 KO and WT mice at the age of four months; there was
little difference in either of the heart weights (Figure 1B, left panel). WT and AKT2 KO hearts with
hematoxylin-eosin (HE) staining indicated that these myocytes have well-ordered myofibrils with
a distinct sarcomeric registry (Figure 1B, left panel), which is consistent with a previous study [18].
Moreover, structures of cardiomyocytes treated with or without AKT2 inhibitors were observed by
immunofluorescence, which showed no difference in cell morphology and area when compared with
control (Figure 1B, right panel), suggesting no significant morphological changes in cardiomyocyte
development due to AKT2 ablation both in vivo and in vitro. Our results indicate that the absence
of AKT2 per se is a trigger of mitochondrial apoptotic genes in the heart but does not influence
cardiomyocyte development under normal circumstance.
2.2. Blockage of AKT2 Facilitates Apoptosis in Cardiomyocytes
In order to explore the role of AKT2 in cardiac apoptosis during ischemia, cultured NRCMs
were treated with AKT2 inhibitor for 3 h before hypoxia treatment, afterwards experimental
ischemia (hereafter, ischemia) was achieved by culturing cells inside a hypoxic incubator in Tyrode’s
solution without serum and glucose. Increased apoptosis was observed in AKT2 inhibitor-treated
cardiomyocytes compared with control during ischemia (Figure 2A,B). Since cardiac fibroblasts (CFs)
are resistant to apoptosis due to their strong expression of the anti-apoptotic factor Bcl-2 [19], in order
to exclude the potential apoptosis stimulated in CFs, which usually exists as contamination during
primary cardiomyocyte isolation, apoptosis was also checked in CFs treated with AKT2 inhibitor.
The results showed that the portion of apoptotic CFs maintained almost the same level of resistance
to apoptosis as control when AKT2 is blocked or not during ischemia (Figure 2C). These data infer
that AKT2 is responsible for cardiac apoptosis under ischemic stimuli and establishes a correlation
between AKT2 inhibition and the elevated apoptosis during cardiac hypoxia.
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Figure 1. AKT2 inhibition triggers apoptosis-related gene expression without affecting cardiac cell 
morphology. (A) left panel: expression of AKT2, phosphorylated AKT2 (p-AKT2), Bax, Bcl-2, 
cytochrome C (Cyto C), apoptosis-inducing factor (AIF), endonuclease G (EndoG) and cleaved 
caspase-3 (cleaved C3) proteins was detected in neonatal cardiomyocytes from 3-day-old rat pups 
treated with or without AKT2 inhibitor at the concentration of 5 and 10 μM for 12 and 24 h 
respectively. Right panel: expression of proteins the same as (A) detected in wild type (WT) and 
AKT2 knockout (KO) mice hearts at 4 months old, 1 and 2 refers to different numbers of heart sample; 
(B) left panel: hearts from WT or AKT2 KO mice at 4 months old and HE staining (×400). Right panel: 
Immunofluorescence staining of α-actinin (red) and hoechst (blue) in neonatal rat cardiomyocytes 
(NRCMs) cultured with or without 10 μM AKT2 inhibitor (AKT2 inhib) for 12 h (×400). Data are 
repeated for three independent experiments. 
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caspase-3 (cleaved C3) proteins was detected in neonatal cardio yocytes from 3-day-old rat pups
treated with or without AKT2 inhibitor at the concentration of 5 and 10 µM for 12 and 24 h respectively.
Right panel: expression of proteins the same as (A) detected in wild type (WT) and AKT2 knockout (KO)
mice hearts at 4 months old, 1 and 2 refers to different numbers of heart sample; (B) left panel: hearts
from WT or AKT2 KO mice at 4 months old and HE staining (×400). Right panel: Immunofluorescence
staining of α-actinin (red) and hoechst (blue) in neonatal rat cardiomyocytes (NRCMs) cultured
with or without 10 µM AKT2 inhibitor (AKT2 inhib) for 12 h (×400). Data are repeated for three
independent experiments.
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Figure 2. Increased apoptosis in cardiomyocytes treated with AKT2 inhibitor during ischemia. (A) 
Detection of Annexin V/Propidium iodide (PI) in cardiomyocytes treated with or without AKT2 
inhibitor (AKT2-inhib, 10 μM) and cultured under normal (con) or ischemia (isch) conditions for 12 h 
by flow cytometry; (B) TUNEL (transferase-mediated deoxyuridine triphosphate-biotin nick end 
labeling) assay of NRCMs with the same treatment as (A); (C) Quantification of apoptotic 
cardiomyocyte fibroblasts (CFs) treated with or without AKT2 inhibitor during ischemia by flow 
cytometry. Values are percentage of apoptotic cells versus total cells in plate. The bars represent the 
mean ± SEM (standard error of mean) of three independent experiments. * p < 0.05, ** p < 0.01 vs. 
control (one-way ANOVA followed by a Tukey test for post hoc analyses). 
2.3. AKT2 Blockage Diminishes the Activation of Extrinsic Apoptotic Signaling Pathway 
We further aimed at providing functional evidence for the role of death receptor-dependent 
(extrinsic) apoptotic pathway in the promotion of ischemic cardiomyocytes with AKT2 inhibition. 
Initiator caspase-8-like activity was measured as an indication of the provocation of the death 
receptor-dependent pathway during ischemic cell death. Although ischemic cardiomyocytes treated 
with Akt2 inhibitor maintained the same level of executioner caspase-8 activity as ischemic NRCMs 
which sustained significantly higher activated caspase-8 than control, there was no significant 
difference when compared with cardiomyocytes treated with AKT2 inhibitors cultivated under 
normal conditions (Figure 3A). This did not show increased apoptosis as proven in Figure 2B. To 
verify this result, pan-caspase inhibitor zVAD-fmk was added to cardiomyocytes during ischemia 
and caspase-8 activity from cell extracts was evaluated. Our data shows no obvious change of 
caspase-8 activity among different treatments (Figure 3A). Moreover, we further ascertained 
reduced expression at transcriptional level for caspase FLICE-like inhibitory protein (cFlip), a 
natural inhibitor of caspase-8 activity [20] (Figure 3B). These data support the conclusion that 
ischemia is not a stimulation for the activation of the extrinsic apoptotic pathway in cardiomyocytes 
with or without AKT2 inhibition. 
Figure 2. Increased a optos s in cardiom ocytes treated with AKT2 inhibito during ischemia.
(A) Detection of An exin V/Propidium iodide (PI) in cardiomyocytes treated with or without AKT2
inhibitor ( 2-i i , µ lt re under normal (con) or ischemia (isch) conditions for 12 h by
flow cytometry; (B) TUNEL (transferase-mediated deoxyuridine triphosphate-biotin nick end labeling)
ssay of NRCMs with the same treatment as (A); (C) Quantification of apoptotic cardiomyocyte
fibroblasts (CFs) treated with or without AKT2 inhibitor during ischemia by flow cytometry. Values are
percentage of apoptotic cells versus total cells in plat . The bars represent the m an ± SEM ( tandard
error of mean) of three independent experim nts. * p < 0.05, ** p < 0.01 vs. control (one-way ANOVA
followed by a Tukey test for p st hoc analyses).
2.3. AKT2 Blockage Diminishes the Activation of Extrinsic Apoptotic Signaling Pathway
e further ai ed at providing functional evidence for the role of eath receptor-dependent
(extrinsic) apoptotic pathway in the promotion of ischemic cardiomyocytes with AKT2 inhibition.
Initiator caspase-8-like activity was measured as an indication of the provocation of the death
receptor-dependent pathway during ische ic ce l death. Although ischemic cardiomyocytes treated
ith KT2 inhibitor maintained the same level of executioner caspase-8 activity as ischemic NRCMs
hich sustained significantly higher activated caspase-8 than control, there was no significant
di ference compared with cardiomyocytes treated with AKT2 inhib tors cultivated under normal
c nditions (Figure 3A). This did not show increased apoptosis as roven in Figure 2B. To v rify this
r sult, pan-caspase i hibitor zVAD-fmk was added to cardiomyocytes uring ischemia a d caspase-8
activity from cell ex racts was evaluated. Our data shows no obvious change of caspase-8 activity
mong different tre tments (Figure 3A). Moreover, we further ascertained an increased expression at
transcriptional level for c spase FLICE-like inhibitory protein (cFlip), a atural inhibitor of aspase-8
activity [20], upon ischemia indu on (Figure 3B). These data support the conclusion that pon AKT2
in ibition, ischemia is not a furt r s imulus for th activation of the ex rinsic apoptotic pathway
in cardiomy cytes.
Int. J. Mol. Sci. 2017, 18, 565 6 of 18
Int. J. Mol. Sci. 2017, 18, 565 6 of 18 
 
 
Figure 3. Inactivation of caspase-dependent apoptosis in ischemic cardiomyocytes treated with an 
AKT2 inhibitor. (A) Initiator caspase-8 activity in extracts of cardiomyocytes with con, an AKT2 
inhibitor, and ischemic cardiomyocytes treated with or without AKT2 inhibitor and/or zVAD; (B) 
Quantitative real time PCR of cFlip transcript in cardiomyocytes with the same treatment as in A. 
zVAD: pan-caspase inhibitor z-VAD-fmk, 100 μM. The bars represent the mean ± SEM of three 
independent experiments. * p < 0.05, ** p < 0.01 vs. control (one-way ANOVA followed by a Tukey 
test for post hoc analyses). ns: not significant. 
2.4. AKT2 Inhibition Promotes Mitochondrial Membrane Injury Independent of Intrinsic Apoptotic Pathway 
To further investigate the mechanism involved in cardiac apoptosis during ischemia when 
AKT2 is inhibited, the role of the caspase-dependent intrinsic apoptotic pathway was evaluated. 
AKT2 is proven to be an inhibitor of Bax [21,22], the induction of which results in downstream 
programming of mitochondrial dysfunction as well as activation of caspase [23,24]. Ischemic 
cardiomyocytes with AKT2 inhibition maintain much higher Bax protein abundance (Figure 4A), 
indicating the provocation of mitochondrial-dependent apoptosis. Mitochondrial-dependent 
apoptosis happens following the disruption of mitochondrial membranes and the release of 
apoptotic proteins located in the intermembrane space thereafter. First to evaluate mitochondrial 
integrity, mitochondrial outer membrane potential (MOMP) was assessed and the result indicates 
serious mitochondrial disruption (Figure 4B), suggesting increased mitochondrial permeability and 
the possible release of mitochondrial-located proteins. 
Since the cytosolic translocation of Cyto C is deemed as the main inducer of 
mitochondiral-dependent apoptosis [25,26,27], the cytosolic distribution of Cyto C was investigated 
in cardiomyocytes with different treatment and the result shows much more intracytosolic 
translocation of Cyto C in ischemic cardiomyocytes with AKT2 blockage (Figure 4C). However, 
activated caspase-9, an initiator caspase which induces apoptosis upon Cyto C translocation to 
cytosol, remained at normal levels in ischemic cardiomyocytes treated with an AKT2 inhibitor, 
Figure 3. Inactivation of caspase-dependent apo t ic cardiomyocytes treated with an
AKT2 inhibitor. (A) Init ator caspase-8 activit i f r io yocytes with con, an AKT2
inhibitor, and ischemic cardio treated with or without AKT2 inhibitor and/or zVAD;
(B) Quan itative real time PCR of cFlip transcript in cardiomyocytes with the same treatment as
in A. zVAD: pan-caspase inhibitor z-VAD-fmk, 100 µM. The bars represent the mean ± SEM of three
independent experiments. * p < 0.05, ** p < 0.01 vs. control (one-way ANOVA followed by a Tukey test
for post hoc analyses). ns: not significant.
2.4. AKT2 Inhibition Promotes Mitochondrial Membrane Injury Independent of Intrinsic Apoptotic Pathway
To further investigate the mechanism involved in cardiac apoptosis during ischemia when AKT2
is inhibited, the role of the caspase-dependent intrinsic apoptotic pathway was evaluated. AKT2 is
proven to be an inhibitor of Bax [21,22], the induction of which results in downstream programming
of mitochondrial dysfunction as well as activation of caspase [23,24]. Ischemic cardiomyocytes
with AKT2 inhibition maintain much higher Bax protein abundance (Figure 4A), indicating the
provocation of mitochondrial-dependent apoptosis. Mitochondrial-dependent apoptosis happens
following the disruption of mitochondrial embranes and the release of apoptotic proteins located
in the inter embra e space thereafter. First to evaluate mitochondrial i tegrity, mitochondrial
outer membrane potential (MOMP) was asse sed and the result indi ates serious mitochondrial
disrupti n (Figur 4B), suggesti g increased mitochondrial permeability and the possible release of
mitochondrial-located proteins.
Since the cytosolic translocation of Cyto C is deemed a the main inducer of mitochondiral-dependent
apoptosis [25–27], the cytosolic distribution of Cyto C was investigated in cardiomyoc tes with
different treatment and the result shows much more intracytosolic translocation of Cyto C in ischemic
cardiomyocytes with AKT2 blockage (Figure 4C). However, activated caspase-9, an initiator caspase
which induces apoptosis upon Cyto C translocation to cytosol, remained at normal levels in ischemic
cardiomyocytes treated with an AKT2 inhibitor, compared with ischemic (isch–con)cardiomyocytes
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(Figure 4D), which obtained significant increase. Moreover, caspase-3 activity was also evaluated
and the result suggested equivalent level of caspase-3 activity in ischemic NRCMs treated with
AKT2 inhibitor compared with cardiomyocytes with AKT2 inhibition under normal conditions,
although there were significant changes compared with control (Figure 4E). These results indicate
that caspase-dependent intrinsic apoptosis is not activated, although mitochondrial injury occurs
during myocardium ischemia when AKT2 is inhibited. Our results also suggested the participation of
caspase-dependent apoptosis during cardiomyocyte ischemia without AKT2 inhibition. To further
verify this conclusion, cardiomyocytes were treated with pan-caspase inhibitor zVAD in addition
to AKT2 inhibitor during ischemia, and cell apoptosis as well as caspase-9 and -3 activity was
evaluated (Figure 4D–F). The data suggested apoptosis was partly blocked in zVAD-treated NRCMs
during ischemia, while there was no change in cardiomyocytes with either AKT2 inhibition or
zVAD-treatment. The decrease of caspase-9 and -3 activity was significant between cardiomyocytes
treated with and without zVAD during ischemia, while there were no obvious changes when AKT2
was inhibited. Taken together, our results above indicate that AKT2 inhibition induces the silencing of
caspase-dependent apoptosis of the internal signaling pathway in cardiomyocytes during ischemia
and hence prompts a distinct cell death signaling pathway that could be provoked by AKT2 inhibition.
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2.5. Cardiac AKT2 Inhibition Facilitates EndoG and AIF Cytosolic and Nucleus Translocation  
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EndoG and AIF are two mitochondrial proteins implicated as pro-apoptotic mediators involved 
in caspase-independent cell death programs by many researchers, and they are proven to be the two 
main inducers of mitochondrial-related cell death when released from mitochondria and 
translocated to nucleus [6,11,25,27]. Therefore, the expression of AIF and EndoG was detected in 
extraction of cardiac cytosolic as well as nucleus protein and also by immunofluorescence staining. 
Both the cytosolic and nucleus translocations of AIF (Figure 5A–C) and EndoG (Figure 5A–C) were 
clearly elevated in ischemic cardiomyocytes treated with and without an AKT2 inhibitor, while the 
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Figure 4. AKT2 inhibition promotes itochondrial injury and cell death without intrinsic apoptosis
activation during cardiac ischemia. (A) Upper panel: Bax abundance was analyzed in total protein
extracts of cardiomyocytes with different treatment; lower panel: Quantification of Bax protein
abundance from western blot. akt2i: AKT2 inhibitor; (B) Mitochondrial outer membrane potential
(MOMP) was evaluated by flow cytometry in normal and ischemic cardiomyocytes treated with or
without an AKT2 inhibitor; (C) Left panel: Cytochrome C (Cyto C) in mitochondrial and cytosolic
extracts in cardiomyocytes treated with or without an AKT2 inhibitor under normal conditions or
ischemia; right panel: Densitometry of western blot bands which was performed with Image J software;
(D,E) Executioner caspase-9 and -3 activity measured in extracts of cardiomyocytes with different
treatment; (F) Detection of AnnexinV/PI by flow cytometry in cardiomyocytes with different treatment as
shown in the figure. zVAD, pan-caspase inhibitor z-VAD-fmk, 100 µM; The bars represent the mean± SEM
of three independent experiments. * p < 0.05, ** p < 0.01 vs. control; # p < 0.05 vs. cells with ischemia
treatment; ns: not significant vs. con (one-way ANOVA followed by a Tukey test for post hoc analyses).
2.5. Cardiac AKT2 Inhibition Facilitates EndoG and AIF Cytos lic and Nucleus Translocation from Mitochondria
EndoG and AIF are two mitochondrial proteins implicated as pro-apoptotic mediators involved
in caspase-independent cell death pr grams by many rese rchers, and they are proven to be the two
main inducers of mitochondrial-related cell death when r leas d from mitochondria and translocated
to nucleus [6,11,25,27]. Therefore, the expression of AIF and EndoG was detected in extraction of
cardiac cytosolic as well as nucleus protein and also by immunofluorescence staining. Both the
cytosolic and nucleus translocations of AIF (Figure 5A–C) and EndoG (Figure 5A–C) were clearly
elevated in ischemic cardiomyocytes treated with and without an AKT2 inhibitor, while the increase of
AIF and EndoG nucleus translocation was much more significant in AKT2-blocked NRCMs during
ischemia (Figure 5B,C). These results suggest that inhibition of AKT2 specifically induces EndoG
and AIF nucleus translocation and activates mitochondrial-dependent DNA degradation in ischemic
myocardium without caspase activation.
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Figure 5. Ischemia induces AIF and EndoG cytosolic and nucleus translocation in cardiomyocytes with
AKT2 inhibition. (A) left panel: Expression of AIF and EndoG was checked by western blot in cytosolic
protein extracts in normal and ischemic cardiomyocytes treated with or without an AKT2 inhibitor;
middle and right panel: protein quantification of EndoG and AIF calculated with Image J software;
(B) left panel: Expression of AIF and EndoG was checked by western blot in nucleus protein extracts in
cardiomyocytes with different treatment as in (A); middle and right panel: protein quantification of
EndoG and AIF calculated with Image J software; (C) Immunofluorescence staining of AIF (green),
EndoG (green) and Hoechst (blue), α-actinin (red), is used as a marker of cardiomyocytes. Scale bar is
20 µm. Each image in this figure is representative of three independent experiments. The bars represent
the mean ± SEM of three independent experiments. * p < 0.05, ** p < 0.01 vs. con; ns: not significant vs.
con (one-way ANOVA followed by a Tukey test for post hoc analyses).
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2.6. Both EndoG and AIF Are Responsible for Caspase-Independent Cell Death When AKT2 is Blocked
The cell death induced by AIF and EndoG nucleus translocation was defined as a unique
process which is distinct from both apoptosis and necrosis due to its specific feature of nucleus
DNA degradation [28]. In apoptotic cells, AIF induces chromatin condensation and large-scale DNA
damage in a caspase-independent manner when translocating from mitochondria to the nucleus [9,29].
EndoG executes DNA damage triggered by Bcl-2/adenovirus E1B 19 kDa protein-interacting protein
3-like (Bnip3) under cell death stimuli including experimental ischemia [7,11,30]. To ascertain the role
of EndoG and AIF in cardiomyocyte apoptosis during ischemia with AKT2 blockage, cardiomyocytes
were transduced with lentiviral vectors carrying small hairpin RNA interference (shRNAi) of Endo G
and AIF respectively or together. Five days after transduction, cardiomyocytes were exposed to AKT2
inhibitor 3 h prior to ischemia (see “Materials and Methods”). The effectiveness of EndoG and AIF
shRNAi vectors were checked by the decrease in AIF and EndoG protein levels measured in protein of
cardiomyocyte total cell lysates (Figure 6A). As shown in our data, increased apoptosis was observed
in ischemic cardiomyocytes compared with control; suppressed AIF or EndoG expression correlates
with a significant reduction of DNA damage to nearly the same level as cardiomyocytes only treated
with AKT2 inhibitor during cardiac ischemia (Figure 6B). These results suggest the indispensable
role of AIF and EndoG in controlling cardiomyocyte DNA degradation during ischemia when AKT2
is blocked.
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Figure 6. Ischemia induces mitochondrial injury and mitochondrial protein translocation in
cardiomyocytes. (A) Expression of AIF and EndoG in 40 µg of protein from total extracts of
cardiomyocytes transduced, scrambled (scr), and transduced with AIF-specific and EndoG-specific
small hairpin RNA interference (shRNAi) construct (shAIF and shEndoG), 5-days post infection.
Prohibitin was used as loading control; (B) Detection of apoptosis by TUNEL in scrambled-transduced
(scr), EndoG-deficient (shEndoG), and AIF-deficient (shAIF) cardiomyocytes treated with or without an
AKT2 inhibitor during ischemia. The bars represent the mean± SEM of three independent experiments.
* p < 0.05 vs. control, # p < 0.05 vs. cells treated with akt2 inhib (one-way ANOVA followed by a Tukey
test for post hoc analyses). ns: not significant.
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3. Discussion
This study reveals a novel role for AKT2 in regulating the apoptotic signaling network during
myocardium ischemia. Our data demonstrate that AKT2 inhibition induces the silencing of caspase
activation which mediates both FADD (Fas-associated death domain)- and mitochondrial-dependent
apoptosis during cardiac ischemia. Our data also show that the blockage of AKT2 leads to the
stimulation of cell death through promoting nucleus translocation of mitochondrial apoptogenic
factors AIF and EndoG in ischemic cardiomyocytes with the absence of caspase activation.
It is well established that the AKT kinase family plays essential roles in protecting the heart
from ischemic injury, however, the mechanism of AKT kinase family affording to cardiac protection is
complicated due to its diverse array of functions within the cardiovascular system, including apoptosis,
proliferation, differentiation, inflammation and autophagy [31,32]. It is proved that AKT2 deficiency
in myocardium during ischemia results in increased apoptosis [13,31], but so far no research has
investigated the mechanism with respect to the apoptotic signaling pathway. In this study we observed
that under normal conditions, there are no morphological changes nor dysfunction of the myocardium
with AKT2 absence or blockage in vitro or in vivo. However, during ischemic stimuli, AKT2 plays
an important role in cardiomyocyte survival by regulating mitochondrial cell death-related gene
expression and translocation.
It is well documented that both necrotic and apoptotic cell death contribute to the pathophysiology
of ischemic injury of the myocardium [33]. However, the Anexin V/PI staining studied with flow
cytometry analysis in our study suggests that despite AKT2 inhibitor treatment, the majority of
cardiomyocytes undergo apoptosis rather than necrosis during ischemia. It is widely accepted
that apoptosis can be triggered by a variety of internal or external signals that are deemed as
FADD-dependent (extrinsic) and mitochondrial-dependent (intrinsic) apoptosis respectively. In our
research, we found that the role of extrinsic apoptosis pathway is inactivated due to the sustained low
caspase-8 activity in AKT2-inhibited cardiomyocytes during ischemia. Therefore, we proposed that
the intrinsic pathway would be the main mechanism.
Cardiac muscle cells rely on mitochondria to obtain energy and even subtle perturbations in
mitochondria content or function can result in cardiac dysfunction [34]. Mitochondria play a key
role as apoptosis occurs through the opening of the mitochondrial permeability transition pore that
is regulated by Bcl-2 family proteins such as Bax [26,35], and the disruption of mitochondrial outer
membrane permeabilization happens secondary to the loss of MOMP during ischemia [8]. The AKT
family is an upstream factor of Bax and negatively regulates Bax expression. The function of Bax during
ischemia has been well documented, and plays a crucial role in mitochondrial-dependent apoptosis
(Bax, cytosolic Cyto C, activated caspase-9 and activated caspase-3) via inducing mitochondrial
permeabilization and therefore the release of apoptogenic factors [25,36,37]. As shown in our data,
significant increases of Bax protein abundance and disrupted MOMP are in accordance with elevated
apoptotic rates observed in cardiomyocytes with AKT2 inhibition during ischemia, suggesting severe
disruption of MOMP with additional AKT2 blockage. Furthermore, as it is well-documented that
MOMP disruption induces Cyto C intracytosolic translocation which subsequently promotes AIF
release from mitochondria [26,38]. Our results show that cytosolic translocation of Cyto C is in parallel
with MOMP elevation, which strengthens our conclusion that mitochondrial permeabilization is
disrupted by AKT2 inhibition during cardiac ischemia, and the release of mitochondrial Cyto C is a
precedent of mitochondrial injury.
We further investigated the role of mitochondrial-dependent (intrinsic) apoptosis in ischemic
cardiomyocytes with AKT2 inhibition. The intrinsic apoptosis has been proven to be related to
caspase-9 activation upon Cyto C release from mitochondria, and activates proapoptotic caspase-3
thereafter [6]. Of interest, neither activated caspase-9 nor caspase-3 was shown in cardiomyocytes with
AKT2 inhibition during ischemia, compared with significantly elevated activity of the two caspases
observed in ischemic cardiomyocytes treated without an AKT2 inhibitor. This result suggests that AKT2
blockage is unrelated to the triggering of the intrinsic apoptotic signaling pathway during ischemia.
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Although caspases have been widely accepted as important mediators of apoptosis, there is
accumulating evidence suggesting the existence of other caspase-independent mechanisms of cardiac
cell death upon various stimuli [9]. It is reported that several mitochondria-located proteins related
to cell survival are released during ischemic stimuli including AIF and EndoG [11,33,39], which are
downstream of Cyto C [26]. Our results reveal that the cytosolic release of AIF and EndoG as well
as their nucleus translocation is significantly promoted in ischemic NRCMs with AKT2 inhibition.
Furthermore, by using lentivirus-driven short-hairpin knockdown RNA (shRNA) of AIF and EndoG
respectively or together in AKT2 inhibitor-treated cardiomoycytes during ischemia, cell death is
attenuated and survival is maintained almost the same level as that of cardiomyocytes only treated with
an AKT2 inhibitor. These results strengthen our conclusion that, other than cardiomyocytes containing
multiple cell death signaling pathways which are both caspase-dependent and -independent during
ischemia, there is a switch to the mitochondrial-related DNA degradation that harms myocardium
survival during cardiac ischemia when AKT2 is blocked.
The current study is the first that elucidates the function and mechanism of AKT2 in
cardiac apoptosis during ischemia. It showed that inhibition of AKT2 activity induces silencing
of both the internal and external apoptotic signaling pathway, while upon the disruption of
MOMP, mitochondrial-dependent cell death was provoked via conducting AIF and EndoG nucleus
translocation and thereafter DNA degradation, thus supporting the conclusion that there is a switch
to the unique mitochondrial-dependent DNA degradation pathway during cardiac ischemia when
AKT2 is inhibited. These findings illustrate the complex function of AKT2 in the heart and suggest
that caution should be exercised when targeting AKT2 as a clinical therapy of myocardium cell death
induced by ischemia injury.
4. Materials and Methods
4.1. Cardiomyocyte Culture, Cardiac Fibroblast Culture and Tissue Samples
The investigation with experimental animals conforms to the Guide for the Care and Use of
Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85–23,
revised 1996). The hearts of 4-month-old AKT2 knockout mice and wild type littermates were
purchased from the Model Animal Resource Information Platform of Nanjing University (#D000054).
We obtained neonatal cardiomyocytes from the hearts of 2–4-day-old Sprague–Dawley rats after
digestion with type-2 collagenase (Worthington, Lakewood, NJ, USA). We used a two-round
pre-plating in order to deplete cardiomyocyte culture of non-myocardial cells. Cells were plated
at a density of 103 cells/mm2 in 2 g/L gelatin-coated FALCON polystyrene dishes (Becton Dickinson,
Palo Alto, CA, USA) and NUNCLON four-well plates (NUNC, Roskilde, Denmark). The medium
used was M199:DMEM (dulbecco’s modified eagle medium) 1:3 (SIGMA-Aldrich, St. Louis, MO,
USA), pH 7.2 with 7.2 mmol/L glucose, 10% horse serum and 5% fetal calf serum (Gibco, New York,
NY, USA). Cardiomyocyte purity was checked by immunocytochemistry with a cardiac sarcomeric
α-actinin monoclonal antibody (clone EA-53, SIGMA-Aldrich, St. Louis, MO, USA), and was found to
be higher than 90% after 24–48 h in vitro.
Cardiac fibroblasts were obtained from the first preplating of cardiomyocyte isolation and cultured
in DMEM with 10% fetal bovin serum (FBS). Cells from passage 2 and 3 were used for the experiments.
Immunocytostaining with antibody to α-actinin identified no positive cells in such cultures.
Deprivation was initiated after 24 h of plating, by culturing cardiomyocytes in DMEM minimal
medium without serum and glucose. We added AKT2 inhibitor CCT128930 (Selleck, Shanghai, China)
at different concentrations when indicated. Cardiac fibroblast cells (CFs) was obtained from the
first pre-plate of cardiomyocyte isolation. We cultured CFs in DMEM-1 % nonessential aminoacids
(SIGMA-Aldrich) and 20% FBS. Different AKT isoform inhibitors were added to the culture medium
at the concentrations and times described in the figures.
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4.2. Experimental Ischemia
Experimental ischemia of NRCMs was performed according to previous protocol which is
described elsewhere [3]. Briefly, medium of cultured neonatal rat cardiomyocytes (NRCMs) were
changed to Tyrode’s solution (NaCl 137 mM, KCl 2.7 mM, Na2HPO4 8 mM, KH2PO4 1.5 mM, CaCl2
0.9 mM, and 0.5 mM, initial pH: 7.2) and incubated inside a hypoxic chamber (Billups-Rothenberg)
in a mixture of 5% CO2 and 95% N2 following manufacturer’s instructions to attain a 0.1% oxygen
concentration for 12 h.
4.3. Histology
Briefly, four mice hearts of each genotype were perfused with paraformaldehyde. Then, the hearts
were embedded in paraffin wax. Serial sections were cut to a thickness of 5–7 µm and processed with
hematoxylin-eosin staining.
4.4. shRNA Knockdown of AKT2, Endo G and AIF
Gene Silencing—In order to obtain the rat-specific small interfering RNA (siRNA) construct,
we designed several primer pairs against the target gene; the selected sequences are shown in
Table 1. The subcloning strategy is based on choosing a sequence into the target gene, which is
19 nucleotides long. Primer annealing was done in 50 mM Hepes pH 7.4, 100 mM NaCl buffer,
using 1 µL of each primer stock (3 mg/mL) to a final volume of 50 µL (primer final concentration
60 µg/m). The protocol for primer annealing consists of progressively reducing the temperature
from 90 to 10 ◦C and increasing time intervals. Annealed primers have protuberant ends compatible
with restriction sites for HindIII and BglII (Takara, Dalian, China), ready to be introduced directly
into pSUPER.retro.puro (Oligoengine Inc., Seattle, WA, USA) previously digested by HindIII and
BglII (Takara). The pLVTHM plasmid is the lentiviral vector used for the transduction of specific
shRNAi into mammalian cells. Therefore, the promoter fragment H1 of pLVTHM was replaced by the
“H1-shRNA” pSUPER fragment, using the restriction sites for EcoRI and ClaI. Finally, we obtained
shRNA constructions into the lentiviral vector and proceeded with the employment of the RNA
interference technique to silence the expression of target genes in cardiomyocytes.
Table 1. Short-hairpin knockdown RNA (shRNA) primer sequences.
Gene Oligonucleotides Sequences (5′→3′)
Endo G
gatccccGGAACAACCTTGAGAAGTAttcaagagaTACTTCTCAAGGTTGTTCCttttta
agcttaaaaaGGAACAACCTTGAGAAGTAtctcttgaaTACTTCTCAAGGTTGTTCCggg
AIF
gatccccGCATGCTTCTATGATATAATTCAAGAGATTATATCATAGAAGCATGCttttta
agcttaaaaaGCATGCTTCTATGATATAATCTCTTGAATTATATCATAGAAGCATGCggg
Scrambled
gatccccGAATGCTAAGATGTCTAATttcaagagaATTAGACATCTTAGCATTCttttta
agcttaaaaaGAATGCTAAGATGTCTAATtctcttgaaATTAGACATCTTAGCATTCggg
We used HEK293T cells as a packaging cell line for lentivirus production [40]. Briefly, the lentiviral
siRNA plasmids were co-transfected with packaging system vector psPAX2 and envelope plasmid
pM2G in the HEK293T cells. Polyetherimide (SIGMA-Aldrich, 408727) transfection method was
used for plasmid co-transfection. The viruses containing siRNA constructs were collected from
the supernatant of HEK293T cell culture and were used for transfecting primary cardiomyocytes.
The efficiency of lentivirus transfection was supervised by checking GFP with an inverted fluorescence
microscope (Carl ZEISS, Axio Vert.A1). The percentage of GFP-positive cells was detected to be
between 90% and 99%.
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4.5. Chemicals
AKT2 inhibitor (Selleck, S2635, 5 µM, 10 µM); pan-caspase inhibitor Z-Val-Ala-Asp (OMe)-CH2F
(z-VAD-fmk) (Selleck, S7023, 100 µM).
4.6. RNA Extraction and Real Time Quantitative RT-PCR
Total RNA was purified with the Trizol Reagent method (Molecular Research Center, Inc.,
Cincinnati, OH, USA) from 1 to 2 × 106 control cardiomyocytes, following the manufacturer’s
instructions. Equal amounts of total RNA were retrotranscribed using ThermoScript reverse
transcriptase (Invitrogen, USA) and random hexamers (Roche Applied Science, Rotkreuz, Switzerland).
The presence of cFlip and Gapdh (glyceraldehyde-3-phosphate dehydrogenase) transcripts was checked
by real-time PCR using specific primers (cFlip Foward 5′–3′: GCAAGGTAGCCAA- GGACAAG;
Reverse 5′–3′: TTTGGGAGAGAAGCCTGGAG; Gapdh Foward 5′–3′: AACGACCCCTTCATTGACCT;
Reverse 5′–3′: CCCCATTTGATGTTAGCGGG). The annealing temperature was 58 ◦C, and elongation
time was 30 s per cycle, in a GeneAmp PCR System 2700 thermocycler (Applied Biosystems, Foster City,
CA, USA).
4.7. Western Blot and Immunofluorescence
At the end of the treatments, cells were scraped from the culture dishes, pelleted, and washed
with ice-cold phosphate-buffered saline (PBS). After lysis in 95 ◦C pre-warmed 125 mM Tris, 2% SDS
(sodium dodecyl sulfate) (pH 6.8), cell lysates were centrifuged, and the supernatant was used as whole
protein cell lysate. Protein concentration was then measured in total and cytosolic extracts by BCA
(bicinchoninic acid) assay (Vazyme, E112-02). SDS-PAGE (sodium dodecyl sulfate- Polyacrylamide gel
electrophoresis) was performed, and protein was electrotransferred to Immobilon-P filters (Millipore,
Bedford, MA, USA, ISEQ00010) and reacted with relevant primary antibodies. Immunoblots were
exposed to appropriate peroxidase-conjugated secondary antibodies and developed with the ECL
(enhanced chemiluminescence) System (Pierce, #32106) or the SuperSigna Substrate (Tanon, #180-5001).
For immunofluorescence detection, cells were grown in a 4-well plate (NUNC, Roskilde, Denmark)
and fixed with 4% paraformaldehyde (PFA), rinsed twice with PBS, and processed as described.
Primary antibodies (Table 2) were diluted in blocking solution (bovin serum, 2% horse serum, 0.1%
Triton, 2% BSA (albumin from bovine serum) diluted in PBS) and incubated for 2 h at room temperature
(RT). Then the wells were washed three times with BS and incubated with the appropriate secondary
antibody for 1 h at RT. Finally, cell nuclei were stained with Hoechst 33342 (SIGMA-ALDRICH, #B2883)
for 30 min at room temperature. Cells were rinsed twice with PBS and mounted in Vectashield
(Vecto Laboratories, Burlingame, CA, USA), which then were observed with inverted fluorescence
microscope (Carl ZEISS, Axio Vert.A1, Dublin, CA, USA).
Table 2. Antibodies (Applications used were IF: Immunofluorescence, WB: Western blot).
Antigen Provider Catalogue Number Application
AKT2 Cell Signaling 3063 WB
P-AKT2 Cell Signaling 8599 WB
Bax Cell Signaling 2772 WB
Cytochrome C Cell Signaling 4272 WB
AIF Cell Signaling 5318 WB
Endonuclease G Abcam Ab76122 WB
Bcl-2 Wanleibio WL01556 WB
Cleaved caspase-3 Cell Signaling 9661 WB
Caspase-8 Cell Signaling 9746 WB
COXIV Cell Signaling 4850 WB
Histon 3 Ruiying Biological RLM3038 WB
Prohibitin NeoMarkers 292P501F WB
GAPDH BBI Life Sciences D110016-0200 WB
α-actinin SIGMA A7811 IF
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Antibodies—Primary antibodies used in this work are shown in Table 2. For immunofluorescence,
secondary antibodies were Alexa Fluor® 594 Goat Anti-Mouse Immunoglobulin G (IgG), Immunoglobulin
A (IgA), Immunoglobulin M (IgM) (H+L) (Invitrogen, A11032) and Alexa Fluor® 488 Goat anti-Rabbit
IgG (H+L) (Invitrogen, A11008).
4.8. Measuremennt of MOMP
MOMP was monitored using the fluorescent dye Rhodamine 123, a cell permeable cationic dye.
Rhodamine 123 was added to cell cultures to attain a final concentration of 10 µM for 30 min at 37 ◦C
at the end of each treatment. The cells were collected and washed twice with PBS and then analyzed
by FACScan flow cytometer (BD, FACS Calibur, New York, NY, USA).
4.9. Measurement of Apoptosis
After treatment, apoptosis was assessed with FITC (Fluoresceninisothiocyanate) Annexin V/PI
kit (BD556547) following the manufacturer’s protocol. Briefly, myocytes were incubated with
annexin V-fluorecein isothiocyanate conjugate at room temperature for 15 min in a humid chamber,
counterstained with propidium iodide, and observed by flowcytometry (BD, FACS Calibur).
4.10. TUNEL Assay
TUNEL (transferase-mediated deoxyuridine triphosphate-biotin nick end labeling) analysis of
cultured myocytes was performed with a commercially available kit for detecting end-labeled DNA
following the manufacturer’s protocol (Beyotime, #C1086) and observed by flowcytometry (BD,
FACS Calibur).
4.11. Enzymatic Caspase Activity Assay
Caspases activities were measured using the caspase-8, -9 and -3 activity assay kit (Beyotime,
C1115, C1151 and C1157) according to the manufacturer’s instructions. Briefly, cultured cardiomyocytes
were washed with cold PBS twice, and resuspended in lysis buffer for 20 min. The lysate was then
centrifuged at 16,000× g at 4 ◦C for 15 min. Caspase-8, -9 and -3 activities were measured by using
reaction buffer and caspases substrate peptides Ac-DEVD-pNA, Ac-IETD-pNA and Ac-LEHD-pNA
respectively. The release of p-nitroanilide (pNA) was qualified by determining the absorbance with
Tecan SUNRISE (Männedorf, Switzerland) at 405 nm.
4.12. Mitochondria, Nuclei and Cytosol Extraction
Cardiomyocytes were washed twice in phosphate-buffered saline (PBS) and once with nuclei
isolation buffer (NB) (10 mM Hepes pH 8.0, 10 mM KCl, 1.5 mM MgCl2, 1 mM dithiothreitol (DTT) and
1 mM phenyl-methylsulfonyl fluoride (PMSF)). Next, they were suspended in NB, allowed to swell on
ice for 15 min and gently lysed with homogenizer. Liberated nuclei were then layered over 30% sucrose
in NB and centrifuged at 800× g for 10 min, followed by washing in NB and suspension in nucleus
membrane lysis buffer (1 M Hepes pH 8.0, 1 M NaCl, 125 mM EDTA (Ethylenediaminetetraacetic acid),
1 mM DTT, 0.2 mM spermine, 1 mM PMSF and 25% glycerol), the lysate was vortexed for 30 s and put
on ice for 10 min. Then, the total lysate was centrifuged at 4 ◦C, 12,000 rpm for 20 min; the supernatant
was nucleus lysate which can be used directly or stored at −20 ◦C for future use.
Mitochondria extraction kit (Beyotime, C3606, Shanghai, China) was used for the isolation of
cardiomyocyte mitochondria and cytosol following the manufacturer’s protocol.
4.13. Statistics
Data are shown as mean ± SEM (standard error of mean). All statistical analyses were performed
using Prism (Graphpad, San Diego, CA, USA) software. Differences between groups were compared by
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one-way ANOVA followed by a Tukey test for post hoc analyses where appropriate. A p-value < 0.05
was considered statistically significant.
5. Conclusions
Our results show that AKT2 inhibition induces a unique mitochondrial-dependent DNA
degradation pathway by activating nucleus translocation of AIF and EndoG during cardiac ischemia,
suggesting a new function and mechanism of AKT2 in regulating cardiomyocyte survival.
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